Is Colinz Labs overvalued or undervalued?

As of 31 October 2025, the valuation grade for Colinz Labs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 39.55, an EV to EBITDA of 14.07, and a ROCE of 10.08%.
In comparison to its peers, Colinz Labs' PE ratio is higher than Sun Pharma's 35.35, which is categorized as expensive, but lower than Divi's Lab's significantly high PE of 77.85, which is very expensive. Other peers like Cipla, with a PE of 22.29, are considered attractive, indicating that Colinz Labs is positioned in the middle of the valuation spectrum within its industry. Recent stock performance shows a decline of 40.47% year-to-date, contrasting sharply with the Sensex's gain of 7.42%, further illustrating the market's cautious stance on Colinz Labs.